FDA: Stop using 'True Man' or 'Energy Max'

May 10, 2007

The U.S. Food and Drug Administration issued a warning Thursday, advising consumers not to purchase or use "True Man" or "Energy Max" products.

Both products, sold as dietary supplements nationwide, are touted as sexual enhancement products and treatments for erectile dysfunction. But the FDA said the products contain potentially harmful, undeclared ingredients.

Specifically, the FDA said the products contain substances called analogs that have structures similar to active ingredients in approved prescription drugs.

The government agency said consumers should discontinue use of both True Man and Energy Max products since it has not approved either and, therefore, their safety and effectiveness have not been established.

Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research, said the undeclared analogs in True Man and Energy Max might interact with nitrates found in some prescription drugs, such as nitroglycerin and medications used to treat diabetes, high cholesterol and heart disease.

Both products are distributed and packed by America True Man Health Inc. of West Covina, Calif.

Copyright 2007 by United Press International

Explore further: Simulation-based training improves endoscopy execution

add to favorites email to friend print save as pdf

Related Stories

The truth about the war on wheat

Oct 03, 2014

If you believe the best-seller lists, the biggest bad in the supermarket aisles is not fat or sodium or sugar, but wheat. We have been warned that eating wheat makes our bellies fatter and triggers diseases ...

Recommended for you

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments : 0